Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure

Group 1 - Iovance Biotherapeutics Inc. expects to achieve full-year 2025 revenue guidance of $250 to $300 million in the first full calendar year of Amtagvi sales [1][2] - Amtagvi, the treatment regimen for advanced melanoma, is projected to have peak sales potential of up to $1 billion [1] - The company has $307 million in cash and cash equivalents, which will fund operations through the second quarter of 2027 [2] Group 2 - Lifileucel, an in-development treatment for lung cancer, has a commercial opportunity that could be up to 7 times larger than the current melanoma treatment market [2] - Enrollment and data updates for Lifileucel are expected to be completed this year, with a launch anticipated in the second half of 2027 [2] - Iovance Biotherapeutics specializes in developing and commercializing cell therapies as novel cancer immunotherapy products [2]